SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its financial results for the three and six months ended June 30, 2025. Corporate Highlights Completed dosing of patients in PRIME Phase 1b Clinical Study of Gemini in CKD Patients Received gross proceeds of $4 million from public offering in May 2025 "The Revelation team con
Related Questions
Did the company disclose any partnership, licensing, or collaboration agreements that could affect future revenue streams?
What is the cash balance and runway after receiving the $4 million public offering proceeds?
Did the company provide any updated guidance or outlook for future quarters?
What is the burn rate and expected cash consumption rate moving forward?
What are the potential risks or upside scenarios associated with the Gemini program's progression?
How will the $4 million capital raise affect dilution for existing shareholders?
What is the anticipated impact of the Phase 1b results on the valuation of REVB?
Are there any upcoming regulatory or clinical trial events that could move the stock price?
What are the expected timelines and milestones for the PRIME Phase 1b Gemini study in CKD patients?
How does REVB's current valuation compare to peers in the inflammation‑rebalancing space?
How did revenue and net loss for the three and six months ended June 30, 2025 compare to prior periods?